Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
376 Leser
Artikel bewerten:
(2)

IBYC AI Healthcare: IBYC Selects Makeer Intelligence as Exclusive Hardware Partner and Launches Canada-Focused Pilot for Multilingual Asian Seniors

IBYC, based in Richmond, BC, is a next-generation digital health company developing AI-powered telemedicine and wearable solutions to improve access to care anytime, anywhere. The company focuses on mobile health monitoring, senior and multilingual populations, and caregiver support through secure, real-time biometric data analysis and AI insights. Founded by entrepreneurs with 20+ years of China-Canada experience, IBYC integrates technology, compliance, and cross-border resources to build scalable, culturally competent healthcare platforms.

Addressing care gaps as 700,000 BC residents lack family doctors and seniors are set to grow 68% over the next two decades

RICHMOND, BRITISH COLUMBIA / ACCESS Newswire / September 18, 2025 / IBYC AI Healthcare Inc. ("IBYC") today announced an exclusive strategic partnership with Makeer Intelligence (Shenzhen) Co., Ltd. ("Makeer") to co-create a new generation of AI-powered health wearables that are designed in Canada and assembled in China. In parallel, IBYC is launching a Canada-focused home health-monitoring pilot for multilingual seniors (55+) and family caregivers, as Canada approaches "super-aged" status with nearly one-quarter of the population over 65 by 2030.

AI digital health mornitor

AI digital health mornitor
AI digital health mornitor product sample.

Market context. Canada faces a shortage of family physicians, with British Columbia alone having roughly 700,000 residents without a family doctor. Seniors are the fastest-growing demographic, accelerating demand for practical, at-home monitoring in a market projected to reach billions by 2033.

Target demographics. IBYC addresses access barriers for Asian seniors, who form a large share of BC's visible-minority population. Studies show cultural and language factors frequently impede access for older Chinese immigrants. During the pandemic, more than seven in ten seniors aged 65-74 used virtual care, indicating strong openness to digital health.

Technology and partnership. IBYC's first-generation device integrates an edge AI chip with sensors for heart rate, HRV, oxygen saturation, sleep, and activity/mobility monitoring. The companion service operates within Canada's privacy framework, offering multilingual experiences tailored for Chinese and South Asian seniors and their families. The BC pilot will evaluate usability, alert responsiveness, and caregiver workload reduction with community clinics and family-physician groups.

Under the partnership, Makeer provides end-to-end manufacturing from prototyping through mass production, while IBYC retains all software, AI algorithms, industrial design, and firmware IP.

Personal health information (PHI) is end-to-end encrypted from device to IBYC's secure cloud, and Makeer is contractually prohibited from accessing, storing, or processing PHI, ensuring compliance with PIPEDA and provincial privacy laws.

Leadership perspective. "With a growing share of primary-care teams using remote monitoring for chronic conditions, we are building on proven adoption," said Iris Wang, Founder and CEO of IBYC. "By combining Canadian AI with Shenzhen's manufacturing expertise, we can deliver culturally competent solutions at scale while maintaining strict privacy controls."

Regulatory positioning. IBYC's current configuration operates as general-wellness, non-medical device technology. Any regulated features will be introduced only after Health Canada authorization, including for machine-learning-enabled functions. Data handling follows PIPEDA with explicit consent for any cross-border coordination.

Availability and scale. The pilot launches this fall in British Columbia with 500 units for usability testing, targeting scale-up based on outcomes. Organizations interested in partnerships can contact info@ibychealth.com for collaboration opportunities.

Contact Information

Iris Wang
CEO
info@dmcompanions.com
778-251-8766

.

SOURCE: IBYC AI Healthcare



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ibyc-selects-makeer-intelligence-as-exclusive-hardware-partner-and-la-1073051

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.